Acetor Tablet 25 mg

Acetor Tablet is a widely prescribed antihypertensive medication containing Captopril 25 mg. Manufactured by Drug International Ltd, this tablet formulation effectively manages mild-to-severe hypertension and congestive heart failure. Priced at ৳3.05 per unit, it offers affordable therapy with a convenient 10×10 strip packaging (৳305.00).

As an ACE inhibitor, Acetor Tablet works by blocking angiotensin-converting enzymes, reducing blood pressure within 1-2 hours of administration. Clinical studies show 60-75% oral bioavailability, with peak effects occurring 60-90 minutes post-dose. Patients must take it on an empty stomach (1 hour before meals) for optimal absorption.

Key indications include:

• Mild-to-moderate hypertension (combined with thiazides)
• Severe resistant hypertension
• Congestive heart failure (with diuretics/digitalis)

Dosage starts at 12.5 mg twice daily, gradually increasing to 50 mg thrice daily. Notable side effects include dizziness (18% patients), dry cough (5-10%), and rare angioedema. Avoid combining with potassium supplements or NSAIDs without medical supervision.

Store below 30°C in moisture-proof containers. Pregnant/nursing women should consult doctors before use. For alternatives, explore other Captopril brands or similar antihypertensive tablets available in Bangladesh.

Adults with mild hypertension: Start with 12.5 mg twice daily, maximum 50 mg twice daily. For heart failure: Initiate with 6.25 mg, gradually increasing to 25 mg thrice daily. Administer 1 hour before meals. Pediatric dosing not established.

Neutropenia, anaemia, proteinuria, hypotension, tachycardia, rashes, usually pruritic may occur. Gastric irritation and abdominal pain may occur.

Pregnancy category D. Fetal toxicity risk in second/third trimesters. Discontinue breastfeeding due to potential infant risks.

Monitor serum creatinine and electrolytes regularly. Avoid tablet crushing/chewing. Use caution in collagen vascular diseases.

Start with lower doses in elderly. Adjust dosing intervals for renal impairment (GFR <30). No hepatic dose adjustment needed. Not approved for pediatric use.

Correction of hypertension would be of primary concern.